BioInvent Will Conduct Phase l/lla Trial With BI-1206 in Combination With Pembrolizumab (Keytruda) in Solid Tumors |
| August 21, 2019 | August 2019 Bond Updates |
|
LUND, Sweden, Aug. 21, 2019 /PRNewswire/ -- BioInvent International AB (publ) (OMXS: BINV), a company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer, today announced that the earlier communicated phase l/lla clinical trial... |
| View more at: https://www.prnewswire.com:443/news-releases/bioinvent-will-conduct-phase-llla-trial-with-bi-1206-in-combination-with-pembrolizumab-keytruda-in-solid-tumors-300904973.html |
| Related News |
|